Tetraphase's eravacycline misses in Phase III cUTI trial

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) reported top-line data showing that IV eravacycline (TP-434) missed the co-primary endpoints in the Phase III IGNITE3 trial to treat complicated urinary tract infections (cUTIs).

On the 1,205-patient

Read the full 310 word article

User Sign In